Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Saved in:
Bibliographic Details
Title: Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Authors: Baumgaertner P; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland., Costa Nunes C; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland., Cachot A; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland., Maby-El Hajjami H; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland; Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland., Cagnon L; Department of Oncology, University Hospital Center (CHUV) , Lausanne, Switzerland., Braun M; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland., Derré L; Urology Research Unit, Urology Department, University Hospital Center (CHUV) , Lausanne, Switzerland., Rivals JP; Department of Otorhinolaryngology - Head and Neck Surgery, CHUV, University of Lausanne , Switzerland., Rimoldi D; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland., Gnjatic S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, USA., Abed Maillard S; Department of Oncology, University Hospital Center (CHUV) , Lausanne, Switzerland., Marcos Mondéjar P; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland; Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland., Protti MP; Tumor Immunology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy., Romano E; Department of Oncology, University Hospital Center (CHUV) , Lausanne, Switzerland., Michielin O; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland; Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland., Romero P; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland; Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland., Speiser DE; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne, Switzerland; Department of Oncology, University Hospital Center (CHUV), Lausanne, Switzerland., Jandus C; Ludwig Cancer Research Center, Department of Oncology, University of Lausanne , Switzerland.
Source: Oncoimmunology [Oncoimmunology] 2016 Sep 09; Vol. 5 (10), pp. e1216290. Date of Electronic Publication: 2016 Sep 09 (Print Publication: 2016).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2162-4011
DOI:10.1080/2162402X.2016.1216290